A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD
0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety
Disorder.